Physician profile
John C Yu
NPI 1922005461
$1,765.39
in general payments reported to CMS, 2019-2025
25 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $44.50 · 2021: $11.16 · 2022: $109 · 2023: $193 · 2024: $346 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690 · Consulting Fee: $550 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.88 |
| Consulting Fee | $550.00 |
| Education | $182.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $221.95 | 2023-2025 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $200.00 | 2025 | Lumryz |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2025 | |
| Harmony Biosciences LLC | $164.98 | 2024-2025 | |
| Grifols USA, LLC | $160.78 | 2019-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $150.00 | 2025 | |
| Mylan Specialty L.P. | $110.29 | 2019-2024 | Yupelri |
| Insmed, INC. | $102.30 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.78 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $53.60 | 2019-2024 | Airsupra |
| Actelion Pharmaceuticals US, INC. | $51.56 | 2022-2023 | Uptravi |
| Baxter Healthcare | $46.34 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $30.42 | 2022-2025 | Dupixent |
| Pulmonx Corporation | $28.71 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Glaxosmithkline, LLC. | $26.15 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $22.36 | 2025 | Sunosi |
| Amgen INC. | $18.39 | 2024 | Tezspire |
| Verona Pharma, INC. | $17.35 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $16.10 | 2024 | Glassia |
| Mallinckrodt Enterprises LLC | $14.82 | 2019 | |
| Genzyme Corporation | $14.70 | 2023 | |
| Gilead Sciences, INC. | $14.12 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.82 | 2019 | |
| Electromed, INC. | $13.81 | 2022 | |
| United Therapeutics Corporation | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.